AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8704837 — intervention group
Group type: EXPERIMENTAL
Intervention: Braden Scale sensory perception subscale score
Number of subjects: 110
Study 1685595 — intervention group
Group type: EXPERIMENTAL
Intervention: Education by video film
Number of subjects: 45
Study 1685595 — intervention group
Group type: EXPERIMENTAL
Intervention: Education by card
Number of subjects: 45
Study 1685595 — intervention group
Group type: COMPARATOR
Intervention: Positive control (education by video film + additional education in a room)
Number of subjects: 45
Study 482028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradimensional oddity shift (CC group)
Number of subjects: 120
Study 482028 — intervention group
Group type: COMPARATOR
Intervention: Extradimensional oddity shift (PC group)
Number of subjects: 120
Study 482028 — intervention group
Group type: COMPARATOR
Intervention: Extradimensional oddity shift (PP group)
Number of subjects: 120
Study 482028 — intervention group
Group type: COMPARATOR
Intervention: Extradimensional oddity shift (CP group)
Number of subjects: 120
Study 31646969 — intervention group
Group type: EXPERIMENTAL
Intervention: PGB diluted with 0.5 mL mepivacaine 1% and long 19G needle
Number of subjects: 108
Study 31646969 — intervention group
Group type: COMPARATOR
Intervention: PGB alone and long 19G needle
Number of subjects: 108
Study 31646969 — intervention group
Group type: EXPERIMENTAL
Intervention: PGB diluted with 0.5 mL mepivacaine 1% and short 21G needle
Number of subjects: 108
Study 31646969 — intervention group
Group type: COMPARATOR
Intervention: PGB alone and short 21G needle
Number of subjects: 108
Study 28182690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 285
Study 28182690 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 285
Study 25816805 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g n‐3 PUFA daily for 3 months
Number of subjects: 162
Study 25816805 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 162
Study 23361260 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic floppy Nissen fundoplication (LNF)
Number of subjects: 125
Study 23361260 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Toupet fundoplication (LTF)
Number of subjects: 125
Study 23361260 — intervention group
Group type: COMPARATOR
Intervention: Both procedures (LNF and LTF)
Number of subjects: 125
Study 17701133 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg for 7 weeks)
Number of subjects: 309
Study 17701133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 15251636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy aiming for strict normoglycemia (80 to 110 mg/dL or 4.5 to 6.1 mmol/L) during intensive care
Number of subjects: 0
Study 15251636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 0
Study 11054443 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic regimen A
Number of subjects: 488
Study 11054443 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic regimen B
Number of subjects: 488
Study 11054443 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge strategy based on clinical response
Number of subjects: 488
Study 9356114 — intervention group
Group type: COMPARATOR
Intervention: O2/NO (Group 2)
Number of subjects: 40
Study 9356114 — intervention group
Group type: COMPARATOR
Intervention: O2 (Group 1)
Number of subjects: 40
Study 9356114 — intervention group
Group type: EXPERIMENTAL
Intervention: O2/NO/almitrine (Group 4)
Number of subjects: 40
Study 9356114 — intervention group
Group type: COMPARATOR
Intervention: O2 (Group 3)
Number of subjects: 40
Study 8455332 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg OFLX once daily
Number of subjects: 40
Study 8455332 — intervention group
Group type: COMPARATOR
Intervention: 600 mg OFLX three times daily
Number of subjects: 40
Study 3513519 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 to 240 mg 2 times a day)
Number of subjects: 19
Study 3513519 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 to 240 mg 2 times a day)
Number of subjects: 19
Study 3513519 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Verapamil and Propranolol)
Number of subjects: 19
Study 3513519 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 19
Study 31317662 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% bimatoprost
Number of subjects: 30
Study 31317662 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% bimatoprost
Number of subjects: 30
Study 31515458 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR antibody treatment (n = 12 class 2, n = 28 class 3)
Number of subjects: 40
Study 31515458 — intervention group
Group type: EXPERIMENTAL
Intervention: First- or second-line anti-EGFR therapy
Number of subjects: 40
Study 31515458 — intervention group
Group type: EXPERIMENTAL
Intervention: Third- or later-line anti-EGFR therapy
Number of subjects: 40
Study 28095527 — intervention group
Group type: EXPERIMENTAL
Intervention: One dental implant
Number of subjects: 36
Study 28095527 — intervention group
Group type: EXPERIMENTAL
Intervention: Two dental implants
Number of subjects: 36
Study 28095527 — intervention group
Group type: COMPARATOR
Intervention: One or two dental implants
Number of subjects: 36
Study 26831734 — intervention group
Group type: EXPERIMENTAL
Intervention: Real bi‐hemispheric tDCS (cathode/anode: C4/C3)
Number of subjects: 16
Study 26831734 — intervention group
Group type: EXPERIMENTAL
Intervention: Uni‐hemispheric tDCS (cathode/anode: Fp3/C3)
Number of subjects: 16
Study 26831734 — intervention group
Group type: COMPARATOR
Intervention: Sham bi‐hemispheric tDCS
Number of subjects: 16
Study 24139233 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (12 sessions)
Number of subjects: 400
Study 24139233 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (18 sessions)
Number of subjects: 400
Study 24139233 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulation (0, 6, 12, or 18 sessions)
Number of subjects: 400
Study 22928389 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1%
Number of subjects: 59
Study 22928389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofene (KTP) 1%
Number of subjects: 59
Study 22928389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofene (KTP) 2%
Number of subjects: 59
Study 22928389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 19579812 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin-containing dialysis fluid
Number of subjects: 11
Study 17502825 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas permeable (GP) lenses
Number of subjects: 14
Study 17502825 — intervention group
Group type: COMPARATOR
Intervention: Non-GP lenses
Number of subjects: 14
Study 14728639 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐beta micronized estradiol
Number of subjects: 27
Study 14728639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12006526 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based therapy (HEC)
Number of subjects: 430
Study 12006526 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based therapy (EC)
Number of subjects: 430
Study 12006526 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
Number of subjects: 430
Study 9819447 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b plus ribavirin (1000 to 1200 mg orally per day for six months)
Number of subjects: 345
Study 9819447 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2b alone (placebo)
Number of subjects: 345
Study 7667050 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension 15 mg/kg/day divided twice a day
Number of subjects: 260
Study 7667050 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin suspension 40 mg/kg/day divided twice or three times a day
Number of subjects: 260
Study 2468932 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg SK&F 86466
Number of subjects: 8
Study 2468932 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg SK&F 86466
Number of subjects: 8
Study 2468932 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg SK&F 86466
Number of subjects: 8
Study 2468932 — intervention group
Group type: COMPARATOR
Intervention: SK&F 86466
Number of subjects: 8
Study 62834 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal/visual feedback
Number of subjects: 267
Study 62834 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific feedback techniques
Number of subjects: 267
Study 62834 — intervention group
Group type: COMPARATOR
Intervention: Three presentation methods
Number of subjects: 267
Study 30248280 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity of midwifery care
Number of subjects: 339
Study 30248280 — intervention group
Group type: COMPARATOR
Intervention: General practitioner and midwife visits
Number of subjects: 339
Study 27692021 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA), single session
Number of subjects: 46
Study 27692021 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 46
Study 26035255 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab plus lenalidomide and dexamethasone
Number of subjects: 646
Study 26035255 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (control group)
Number of subjects: 646
Study 23910791 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of food cravings
Number of subjects: 0
Study 23910791 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of food cravings
Number of subjects: 0
Study 23910791 — intervention group
Group type: COMPARATOR
Intervention: Control (allowed to eat from the food)
Number of subjects: 0
Study 21288351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (1600 mg with meals for 4 weeks, then randomized to continue for 36 weeks)
Number of subjects: 120
Study 21288351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to sevelamer carbonate, for 36 weeks)
Number of subjects: 120
Study 21288351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 120
Study 21288351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 18727661 — intervention group
Group type: EXPERIMENTAL
Intervention: On‐St group (patients on steroids at 15th day after transplantation)
Number of subjects: 148
Study 18727661 — intervention group
Group type: COMPARATOR
Intervention: Off‐St group (patients not on steroids at 15th day after transplantation)
Number of subjects: 148
Study 18727661 — intervention group
Group type: EXPERIMENTAL
Intervention: On‐St group
Number of subjects: 148
Study 18727661 — intervention group
Group type: COMPARATOR
Intervention: Off‐St group
Number of subjects: 148
Study 16452695 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment
Number of subjects: 198
Study 16452695 — intervention group
Group type: COMPARATOR
Intervention: Standard Clinical Case Management
Number of subjects: 198
Study 15323594 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine dose increase
Number of subjects: 55
Study 15323594 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation of fluoxetine
Number of subjects: 55
Study 15323594 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine augmentation of fluoxetine
Number of subjects: 55
Study 11732814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nasal spray (IBNS) 80 microg twice per day (b.i.d.)
Number of subjects: 144
Study 11732814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 9417265 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl bolus injection (20 ml)
Number of subjects: 0
Study 9417265 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual bolus tracking
Number of subjects: 0
Study 9417265 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index, injection flow, and contrast material volume
Number of subjects: 0
Study 7525120 — intervention group
Group type: COMPARATOR
Intervention: Once daily GH injection (3 IU/m2/24 h in the evening)
Number of subjects: 8
Study 7525120 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily GH injections (3 IU/m2, two-thirds in the evening and one-third in the morning)
Number of subjects: 8
Study 7525120 — intervention group
Group type: COMPARATOR
Intervention: Once daily GH injection
Number of subjects: 8
Study 7525120 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily GH injections
Number of subjects: 8
Study 3116111 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of paracetamol
Number of subjects: 77
Study 3116111 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of diflunisal
Number of subjects: 77
Study 3116111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 3116111 — intervention group
Group type: EXPERIMENTAL
Intervention: First and second doses of paracetamol
Number of subjects: 77
Study 3116111 — intervention group
Group type: EXPERIMENTAL
Intervention: First and second doses of diflunisal
Number of subjects: 77
Study 30355428 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crowns (ZC)
Number of subjects: 13
Study 30355428 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel crowns (SSC)
Number of subjects: 13
Study 30355428 — intervention group
Group type: COMPARATOR
Intervention: Intact contralateral primary molars (Control)
Number of subjects: 13
Study 27659879 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (2 g)
Number of subjects: 1200
Study 27659879 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (6 g)
Number of subjects: 1200
Study 27659879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 24689247 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-wandering
Number of subjects: 0
Study 24689247 — intervention group
Group type: COMPARATOR
Intervention: On-task
Number of subjects: 0
Study 22535858 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 4136
Study 20012223 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet rich in animal fat from linseed-fed animals
Number of subjects: 160
Study 20012223 — intervention group
Group type: COMPARATOR
Intervention: Control diet with less animal fat and higher PUFA/SFA ratio
Number of subjects: 160
Study 20012223 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet
Number of subjects: 160
Study 20012223 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 160
Study 20012223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 160
Study 19038899 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 or 400 mg daily)
Number of subjects: 88
Study 19038899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 15794777 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck mucosal eversion
Number of subjects: 100
Study 15794777 — intervention group
Group type: COMPARATOR
Intervention: No bladder neck mucosal eversion
Number of subjects: 100
Study 15794777 — intervention group
Group type: EXPERIMENTAL
Intervention: Early urinary extravasation
Number of subjects: 100
Study 14627476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lap-Band system (INAMED)
Number of subjects: 60
Study 14627476 — intervention group
Group type: COMPARATOR
Intervention: Heliogast band (Hélioscopie)
Number of subjects: 60
Study 10871568 — intervention group
Group type: EXPERIMENTAL
Intervention: Carb + Pro trial (0.8 g carbohydrate*kg(‐)(1)*h(‐)(1) plus 0.4 g wheat protein hydrolysate plus free leucine and phenylalanine*kg(‐)(1)*h(‐)(1))
Number of subjects: 8
Study 10871568 — intervention group
Group type: EXPERIMENTAL
Intervention: Carb + Carb trial (1.2 g carbohydrate*kg(‐)(1)*h(‐)(1))
Number of subjects: 8
Study 10871568 — intervention group
Group type: COMPARATOR
Intervention: Carb trial (0.8 g carbohydrate*kg(‐)(1)*h(‐)(1))
Number of subjects: 8
Study 8804876 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b, 3 MU thrice weekly for 6 months (n = 26)
Number of subjects: 60
Study 8804876 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b, 3 MU thrice weekly for 12 months (n = 34)
Number of subjects: 60
Study 8804876 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b, 3 MU thrice weekly for 6 months
Number of subjects: 60
Study 8804876 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b, 3 MU thrice weekly for 12 months
Number of subjects: 60
Study 1473321 — intervention group
Group type: EXPERIMENTAL
Intervention: Total breast-fed for at least 2 months
Number of subjects: 426
Study 1473321 — intervention group
Group type: EXPERIMENTAL
Intervention: Total breast-fed for at least 3 months
Number of subjects: 426
Study 1473321 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breast-fed for at least 2 months
Number of subjects: 426
Study 1473321 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively breast-fed for at least 3 months
Number of subjects: 426
Study 1473321 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary milk feeding begun at younger than 2 months
Number of subjects: 426
Study 1473321 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary milk feeding begun at younger than 3 months
Number of subjects: 426
Study 6380886 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 0
Study 6380886 — intervention group
Group type: COMPARATOR
Intervention: meglumine iothalamate
Number of subjects: 0
Study 31128228 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ANP, BNP, or Pro‐BNP (cutoffs of >77, 100, and 900 pg/mL, respectively)
Number of subjects: 97
Study 31128228 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP or Pro‐BNP
Number of subjects: 97
Study 31128228 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated ANP alone
Number of subjects: 97
Study 28181844 — intervention group
Group type: EXPERIMENTAL
Intervention: New model of care (transprofessional role intervention)
Number of subjects: 58
Study 28181844 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 58
Study 25417174 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAT Cancer intervention
Number of subjects: 222
Study 23841266 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiling pa'an granule (GPG)
Number of subjects: 121
Study 23841266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 21740238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof‐Lex aluminum oxide disc technique
Number of subjects: 60
Study 21740238 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbide bur finishing and Astrobrush polishing technique
Number of subjects: 60
Study 21740238 — intervention group
Group type: COMPARATOR
Intervention: Mylar matrix strips (control group)
Number of subjects: 60
Study 21740238 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofilled composite (Filtek Z350)
Number of subjects: 60
Study 19178965 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-DM
Number of subjects: 987
Study 19178965 — intervention group
Group type: COMPARATOR
Intervention: CKD-only
Number of subjects: 987
Study 16484991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (75% VO2max, 3 times/week, 40 min/session for 6 months)
Number of subjects: 31
Study 16484991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 31
Study 12460129 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtyping classifications based on gender, onset age, family history, externalizing disorders, internalizing disorders, and temperament.
Number of subjects: 600
Study 12460129 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalizing disorders, onset age, difficult temperament, and internalizing disorders.
Number of subjects: 600
Study 12460129 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months.
Number of subjects: 600
Study 11072435 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 27
Study 11072435 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg nicotine patch (Nicotrol)
Number of subjects: 27
Study 11072435 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-mg nicotine patch (Nicoderm)
Number of subjects: 27
Study 11072435 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nicotine patches (Nicotrol and Nicoderm)
Number of subjects: 27
Study 7540147 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF (recombinant human granulocyte-macrophage colony-stimulating factor)
Number of subjects: 18
Study 7540147 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (historical control group)
Number of subjects: 18
Study 2025787 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment for 12 months
Number of subjects: 0
Study 7031725 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 3
Study 7031725 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 3
Study 7031725 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3
Study 6617110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide-spironolactone combination (25 mg B.I.D.)
Number of subjects: 80
Study 6617110 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide-spironolactone combination (50 mg O.I.D.)
Number of subjects: 80
Study 30022362 — intervention group
Group type: EXPERIMENTAL
Intervention: IV paracetamol 1000 mg in 100 ml solution (Group P)
Number of subjects: 150
Study 30022362 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ibuprofen 800 mg in 100 ml saline (Group I)
Number of subjects: 150
Study 30022362 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C, 100 ml saline solution)
Number of subjects: 150
Study 27677474 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser enucleation of the prostate (ThuLEP)
Number of subjects: 158
Study 27677474 — intervention group
Group type: COMPARATOR
Intervention: Plasmakinetic bipolar resection of the prostate (PKRP)
Number of subjects: 158
Study 27677474 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures (ThuLEP and PKRP)
Number of subjects: 158